Difference between revisions of "Talquetamab (Talvey)"
Jump to navigation
Jump to search
m |
Warner-admin (talk | contribs) m (Text replacement - "/CD3 bispecific" to "-CD3 bispecific") |
||
Line 18: | Line 18: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
− | [[Category:Anti-GPRC5D | + | [[Category:Anti-GPRC5D-CD3 bispecific antibodies]] |
[[Category:Multiple myeloma medications]] | [[Category:Multiple myeloma medications]] |
Latest revision as of 00:13, 18 October 2023
Mechanism of action
From the NCI Drug Dictionary: A bispecific humanized monoclonal antibody against human CD3, a T-cell surface antigen, and human G-protein coupled receptor family C group 5 member D (GPRC5D), a tumor-associated antigen (TAA), with potential antineoplastic activity. Upon administration, talquetamab binds to both CD3 on T cells and GPRC5D expressed on certain tumor cells. This results in the cross-linking of T-cells and tumor cells, and induces a potent cytotoxic T-lymphocyte (CTL) response against GPRC5D-expressing tumor cells.
Toxicity management
Diseases for which it is established
History of changes in FDA indication
- 2023-08-09: Granted accelerated approval for adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. (Based on MonumenTAL-1)
Also known as
- Code name: JNJ-64407564
- Generic name: talquetamab-tgvs
- Brand name: Talvey